• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Diagnostics

Labcorp launches at-home collection device for diabetes risk testing

May 17, 2022 By Sean Whooley

Labcorp Weavr Velvet

Labcorp (NYSE:LH) announced today that it launched an at-home collection kit that measures HbA1c from a small blood sample. Burlington, North Carolina-based Labcorp’s first-of-its-kind diagnostic offering uses a collection device from Weavr Health and is offered through its Labcorp OnDemand platform. The company said in a news release that it’s the only commercial laboratory to […]

Filed Under: Diabetes, Diagnostics, Featured Tagged With: LabCorp, Weavr Health

BD ticks up on Street-beating Q4, sets 2022 guidance range

November 4, 2021 By Sean Whooley

This is the logo of BD.

BD (NYSE:BDX) shares rose today on fourth-quarter results that came in ahead of the consensus forecast. The Franklin Lakes, New Jersey-based medtech posted profits of $242 million, or 84¢ per share, on sales of $5.1 billion for the three months ended Sept. 30, 2021, more than doubling its bottom line on sales growth of 7.3%. Get […]

Filed Under: Business/Financial News, Diagnostics, Drug-Device Combinations, Featured, MassDevice Earnings Roundup, Wall Street Beat Tagged With: BD, coronavirus, COVID-19

Thermo Fisher Scientific expands corporate leadership team

July 7, 2021 By Sean Whooley

Thermo Fisher

Thermo Fisher Scientific (NYSE:TMO) announced today that it appointed Dr. Alan Sachs to chief medical officer and Karen E. Nelson to chief scientific officer. Sachs served as Waltham, Mass.-based Thermo Fisher’s CSO since 2016 and will be succeeded by Nelson as he assumes the newly established CMO position at the company. Both will join the […]

Filed Under: Business/Financial News, Diagnostics, Drug-Device Combinations, Featured, Pharmaceuticals Tagged With: Personnel, Personnel Moves, thermofisherscientific

Cardinal Health wins new FDA approval for Lymphoseek

June 10, 2021 By Sean Whooley

Cardinal Health

Cardinal Health (NYSE:CAH) announced today that the FDA approved its Lymphoseek injection for pediatric use. Dublin, Ohio-based Cardinal Health touts Lymphoseek — acquired from Navidea Biopharmaceuticals (NYSE:NAVB) in November 2016 — as the first and only radiopharmaceutical agent specifically designed for targeted lymphatic mapping and guiding sentinel lymph node biopsies (SLNB). The new indication will expand […]

Filed Under: Diagnostics, Drug-Device Combinations, Featured, Oncology, Pediatrics, Pharmaceuticals Tagged With: Cardinal Health, FDA

BlueStar Genomics gains breakthrough nod for pancreatic cancer test

March 31, 2021 By Sean Whooley

Bluestar Genomics

Bluestar Genomics announced today that it received FDA breakthrough device designation for its pancreatic cancer test. San Diego-based Bluestar’s proprietary noninvasive pancreatic cancer detection test is designed for use with patients with new-onset diabetes, according to a news release. The test uses a standard blood draw to assess whether an individual has an abnormal epigenomic […]

Filed Under: Clinical Trials, Diabetes, Diagnostics, Featured, Food & Drug Administration (FDA), Regulatory/Compliance Tagged With: Bluestar Genomics, FDA

How CGM tech has advanced in the 21st century

March 11, 2021 By Brian Buntz

CGMs Diabetes 21st Century Dexcom Medtronic Abbott Senseonics

The rapid evolution of the continuous glucose monitor (CGM) has brought flexibility and convenience to diabetes control. Continuous glucose monitors (CGMs) have transformed how many people with diabetes manage blood sugar, but attempts to monitor blood glucose have a long history. Efforts to manage glucose kicked off in earnest when researchers began measuring glucose in […]

Pages: Page 1 Page 2 Page 3 Page 4 Page 5 Page 6

Filed Under: Diabetes, Diagnostics, Drug-Device Combinations, Featured Tagged With: abbott, CGM, Dexcom, Medtronic, Senseonics

PerkinElmer completes Oxford Immunotec acquisition

March 9, 2021 By Sean Whooley

PerkinElmer oxford immunotec

PerkinElmer (NYSE:PKI) announced today that it completed its previously announced acquisition of Oxford Immunotec. Under the acquisition agreement announced in January, London-based Oxford Immunotec’s shareholders will be entitled to receive $22 for each outstanding ordinary share, with the terms of the acquisition valuing Oxford Immunotec’s entire issued and to-be-issued ordinary share capital at $591 million. […]

Filed Under: Business/Financial News, Diagnostics, Drug-Device Combinations, Featured, Mergers & Acquisitions, Respiratory Tagged With: Oxford Immunotec, perkinelmer

Navidea enters into $5M private placement

March 2, 2021 By Sean Whooley

Navidea Biopharmaceuticals

Navidea Biopharmaceuticals (NYSE:NAVB) announced today that it entered into a private placement worth $5 million. Dublin, Ohio-based Navidea’s agreement comes with its largest shareholder, John K. Scott, Jr., for the purchase of $5 million in newly-designated Series E redeemable convertible preferred stock, according to a news release. Over the course of the next 18 months, the […]

Filed Under: Business/Financial News, Diagnostics, Drug-Device Combinations, Featured, Funding Roundup, Pharmaceuticals Tagged With: Navidea Biopharmaceuticals

PerkinElmer to acquire Oxford Immunotec

January 7, 2021 By Sean Whooley

PerkinElmer oxford immunotec

PerkinElmer (NYSE:PKI) and Oxford Immunotec announced today that they agreed to terms under which the former will acquire the latter. Under the agreement, London-based Oxford Immunotec’s shareholders will be entitled to receive $22 for each outstanding ordinary share, with the terms of the acquisition valuing Oxford Immunotec’s entire issued and to-be-issued ordinary share capital at $591 […]

Filed Under: Business/Financial News, Diagnostics, Drug-Device Combinations, Featured, Mergers & Acquisitions, Respiratory Tagged With: Oxford Immunotec, perkinelmer

Biolinq names new CEO

November 12, 2020 By Sean Whooley

Biolinq

Wearable biosensor technology developer Biolinq announced today that it named Richard Yang as its new CEO. San Diego-based Biolinq, which develops biosensor platforms to measure continuous glucose for managing diabetes, among other clinical conditions, said in a news release that Yang is a veteran of more than 20 years with time spent at top-tier medical device companies. […]

Filed Under: Diabetes, Diagnostics, Featured, Personnel Tagged With: biolinq

  • « Go to Previous Page
  • Page 1
  • Page 2
  • Page 3
  • Page 4
  • Interim pages omitted …
  • Page 16
  • Go to Next Page »

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS